CHRU de LILLE - Claude Huriez
CHRU de LILLE - Claude Huriez
Lille, France3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 3 | 2026-06-15 | NCT06006117 | |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | diffuse large B-cell lymphoma | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04974216 | |
| Glofitamab in Real Life | large B-cell lymphoma | Recruiting | Not stated | 2026-06-03 | NCT06994169 |